JUN 03, 2016 8:46 AM PDT

FDA Clears New Diagnostic Agent for Detection of Rare Tumors

WRITTEN BY: Xuan Pham
After earning priority review status, the French-based pharmaceutical company Advanced Accelerator Applications just received FDA approval for a new agent to image neuroendocrine tumors (NET). Marketed under the name Netspot, the kit prepares a radioactive agent that helps doctors spot and treat the rare tumors. Outside of the U.S. Netspot is known as Somakit-TATE.

"Use of advanced imaging techniques to detect rare neuroendocrine tumors at an early stage in patients is critical," said Libero Marzella, director of the Division of Medical Imaging Products in the FDA's Center for Drug Evaluation and Research. "Netspot provides another diagnostic tool whose results will help clinicians determine the location and extent of the tumor. This information is important for planning the appropriate course of therapy."

Neuroendocrine tumors (NETs) form from abnormal neuroendocrine cells, which are hormone cells found throughout the body, especially in the lungs, stomach and intestines. This tumor type is rare, but still affects over 47,000 people in the US and European Union annually. Sometimes benign but sometimes cancerous, the tumor can lurk undetected for years and delay diagnosis and treatment. Thus with surgery, chemotherapy, and/or radiotherapy interventions, the five-year survival rate still hovers between 50 to 60 percent.
 

Netspot is a diagnostic solution to detecting NETs. The single-dose kit prepares a radioactive substance, known as gallium Ga 68 dotatate, as an injectable. This radioconjugate has the capacity to bind to somatostatin receptors that are present on the hormone-producing NETs. Then, positron emission tomography (PET) imaging reveals the locations of these tumors. Uptake of the Ga 68 dotatate also reveals the density of the tumors. From a chemical affinity perspective, Ga 68 dotatate binds to the somatostatin receptors much stronger than the body’s somatostatin hormone. This allows for clear and accurate visualization of the tumors, if they are present.

The new intervention has already undergone three clinical trials, in which its safety and efficacy was stringently tested. In one of the trials, the company compared Netspot against standard imaging techniques and demonstrated that Netspot performed better. They reported no adverse reactions from Netspot.

Following the approval, the company plans to make Netspot available to doctors as soon as possible. They note that although NETs are designated as rare tumors, otherwise called an “orphan disease,” the incidence of this tumor has grown over 500 percent over the past 30 years. As such, making better diagnostic tools available for the detection of these tumors can yield better outcome for the patients involved.

Additional source: Advanced Accelerator Applications press release
About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
OCT 26, 2020
Cancer
Attacking leukemia trojan horse style
OCT 26, 2020
Attacking leukemia trojan horse style
Researchers from the Max Planck Institute of Biochemistry have developed a new approach to targeting leukemic stem cells ...
NOV 11, 2020
Cancer
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
NOV 11, 2020
A New CDK Inhibitor Could Help with Unresponsive Liver Cancer
Amongst the most common targets of anti-cancer drugs are small regulatory molecules called cyclin-dependent kinases (CDK ...
NOV 10, 2020
Cardiology
Liposomal Delivery Could Help Prevent Doxorubicin Cardiotoxicity
NOV 10, 2020
Liposomal Delivery Could Help Prevent Doxorubicin Cardiotoxicity
One of the greatest failures of modern cancer therapies is the rather substantial off-target toxic effects many radio-, ...
NOV 18, 2020
Cancer
Could Targeting the Proteasome be Effective Against Cancer?
NOV 18, 2020
Could Targeting the Proteasome be Effective Against Cancer?
One of the trickiest things about anti-cancer drug design is targeting. Today, most drugs on the market target critical ...
NOV 23, 2020
Cancer
Platelets May Protect Cancer Against PD-1 Therapies
NOV 23, 2020
Platelets May Protect Cancer Against PD-1 Therapies
One of cancer’s greatest tools is its ability to manipulate the immune system. Many cancer therapies have arisen t ...
NOV 14, 2020
Cancer
New intravenous anti-cancer therapy crosses blood-brain barrier
NOV 14, 2020
New intravenous anti-cancer therapy crosses blood-brain barrier
New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is abl ...
Loading Comments...